A multi-omics microbiome signature is associated with the benefits of gastric bypass surgery and is differentiated from diet induced weight loss through 2 years of follow-up
Vancheswaran Gopalakrishnan(AstraZeneca (United States)), Taylor S. Cohen(AstraZeneca (Netherlands)), Ian Henry(AstraZeneca (Sweden)), Khader Shameer(Target (United States)), Ida Robertsen(University of Oslo), Peter J. Greasley(AstraZeneca (Sweden)), Rune Sandbu(Uppsala University), Shalini Andersson(AstraZeneca (Sweden)), Jens Kristoffer Hertel(Sykehuset i Vestfold), Bret R. Sellman(AstraZeneca (United States)), Rasmus Jansson‐Löfmark(AstraZeneca (Sweden)), Cecilia Karlsson(National Academy of Medicine), Jøran Hjelmesæth(University of Oslo), Chanchal Kumar(Vignana Jyothi Institute of Management), Hege Christensen(University of Oslo), Line Kristin Johnson(Sykehuset i Vestfold), Christopher Morehouse, Ben Sparklin(AstraZeneca (United States)), Anders Åsberg(Oslo University Hospital)
Cited by 1